- The scientific and clinical communities have a better understanding of and access to experimental monoclonal antibodies for the prevention and treatment of emerging or re-emerging viral infections, as well as for further clinical investigation. - Candidate monoclonal antibody therapies are available to treat patients for emerging and re-emerging viral infections, increasing therapeutic options for clinical deployment in case of an epidemic or pandemic. Infectious diseases remain a major threat to health and health security in the EU and globally.
The conditions for qualifying. An eligibility check tests your details against each one.
At least 3 independent partners
Does your company qualify?
Give a few facts about your company and project, and see for each condition whether you meet it.
Eligibility checkThe EIC STEP Scale Up call offers a total indicative budget of EUR 300 million for 2026, which is expected to rise to EUR 900 million for the period 2025-2027. Any unused amount from this b…
The EIC Accelerator supports companies (principally SMEs, including start-ups) to scale up high impact innovations with the potential to create new markets or disrupt existing ones. The EIC…
Grant from SBEP (EU-funded project) across the EU. Total budget €37,723,260. Applications until 16 November 2026.
A check is an indication from the published conditions and the facts you give. Only the competent authority decides whether you are eligible.